share_log

东吴证券4月23日发布研报称,给予科拓生物(300858.SZ)买入评级。评级理由主要包括:1)下游需求快速扩张拉动上游市场规模成长;2)上游高壁垒,国产替代进行时;3)战投引入+激励落地,益生菌第一股加速战略转型;4)研发+服务双轮驱动,公司益生菌业务成长性可期。(每日经济新闻)

Dongwu Securities released a research report on April 23 stating that it gave Koto Biotech (300858.SZ) a purchase rating. The main reasons for the rating include: 1) the rapid expansion of downstream demand driving the growth of the upstream market; 2) hi

Zhitong Finance ·  Apr 23, 2024 07:45
Dongwu Securities released a research report on April 23 stating that it gave Koto Biotech (300858.SZ) a purchase rating. The main reasons for the rating include: 1) the rapid expansion of downstream demand driving the growth of the upstream market; 2) high upstream barriers, when domestic substitution is carried out; 3) the introduction of war investment+incentive implementation, and the first probiotic stock accelerates strategic transformation; 4) R&D and service are two-wheel drive, and the growth of the company's probiotic business can be expected. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 259

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.